Switching to an alternative biological agent in juvenile idiopathic arthritis (I)
Gonzalez MI, Murias S, Remesal A and 2 more
Pediatric Rheumatology Online Journal · 2011
doi:10.1186/1546-0096-9-s1-p162 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
BackgroundJuvenile idiophatic arthritis (JIA) is a heterogeneous disease and it's associated with an increased use of various biological agents in recent years. AimDescribe changes in treatment with biological agents in JIA patients. MethodsThis is a retrospective study of 109 JIA patients from a tertiary centre.Variables included were: age, disease duration, sex, antinuclear antibodies (ANA), HLA B27, Rheumatoid Factor (RF), uveitis and data of systemic AIJ.Current and previous biological agents, reasons for change and adverse events were also recorded.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.